Skip to main content
. 2023 Dec 14;15(12):2779. doi: 10.3390/pharmaceutics15122779

Figure 4.

Figure 4

Detection of HSA complexes with TZD30/M30-FAM by EMSA; oligonucleotide samples contained 10 µM oligomer; * indicates an ON:HSA ratio. HSA (Lane 1), M30-FAM (Lane 2), TZD30 (Lane 3), TZD30/M30-FAM (Lane 4), and TZD30/M30-FAM + HSA (Lanes 4–8). Region-corresponding mobilities of the HSA–oligonucleotide complexes under the conditions used are marked with a blue curly bracket, and the range of mobility of free oligonucleotides is marked with a red curly bracket.